The medicine of the future is already here. Thanks to technological advances such as big dataOr automation or artificial intelligence, which allows the different health sectors to provide more flexibility and creativity in developing treatments, so it is possible today to provide personalized care for each patient.
Technologically, very useful applications are already available for diagnosing diseases such as heart failure or chronic kidney disease. According to Dr. Cesar Velasco, Director of Innovation and Digital Strategy at AstraZeneca, these are “two different diseases but they are completely related and we must treat them together. Thanks to digitization, primary care and other medical specialties that treat these two diseases can be more connected and achieve a more comprehensive follow-up of patients.”
Through digitization, the value of health data can be maximized by optimizing the use of data. big data. There is a large amount of data in clinical histories that can actually help diagnose diseases such as chronic kidney disease earlier. Thanks to public-private collaboration, PREVENT has already been launched, an initiative led by the Spanish Society of Family and Community Medicine (SemFYC) sponsored by AstraZeneca in Extremadura through which chronic kidney disease can be diagnosed with the data that the health system already has on patients.
Thanks to the AI voice recording application, possible changes in the course of the patient’s heart failure condition are detected
Cesar Velasco, Director of Innovation and Digital Strategy at AstraZeneca
For such examples, AstraZeneca prioritizes data management and analysis to develop innovative therapies, and the use of big data improves interpretation of symptoms, communication of results and patient experience.
“Through artificial intelligence” – says Cesar Velasco – “we identify specific diseases or exacerbations of heart failure, and prevent hospitalizations that could be avoided. New horizons are opening up for scientific innovation that allow not only more personalized medicine, but also greater sustainability of the health system”. In this context, AstraZeneca is undergoing a digital transformation aimed at maximizing the scope of all its activities; From the scientific development of new molecules to the reformulation of chemistry. The goal is always to make traditional treatments more efficient or to design new ones with an innovative character.
A revolution in diagnosis
Heart failure is a chronic condition that affects 2.34% of the Spanish adult population and is the leading cause of hospitalization for people over 65 years of age. Direct, convenient and easy monitoring through patient speech, using AI acoustic vital signs, is the basis of the Cordeo project.
It is a mobile application that records the patient daily, alerting health professionals about signs of deterioration or possible complications so that they can act immediately. The tracking is done using a speech processing technology called HearO TM, developed by the Israeli company Cordio.
AstraZeneca has already launched the first real test of this system in collaboration with Belvig University Hospital and Bilvvig Institute for Biomedical Research (IDIBELL). César Velasco is confident that these pilot projects can be adapted to more hospitals: “With this project we are advancing the identification of symptoms from our homes. This new technology allows us to significantly improve the diagnosis of metastatic disease, as well as better monitor symptoms.”
Digital vital signs
It’s still a project, but it’s already in the works. This is the CKD (Chronic Kidney Disease) Challenge, which aims to promote the development of innovative technological solutions to accelerate diagnosis and reduce the burden of chronic kidney disease. The challenge is to identify innovative solutions that contribute to early diagnosis through technologies such as digital biomarkers and wearable devices, which will integrate artificial intelligence and machine learning, big data or the Internet of Things. This call for open innovation was held within the framework of the South Summit 2022 event. Of all the projects submitted, the winner of the CKD Challenge will participate with AstraZeneca for pilot project development, and will have access to experts from innovation centers around the world. the world. world and can be expanded internationally.
AstraZeneca maintains an alliance with start Idoven, the first cardiology platform with artificial intelligence to identify, classify and diagnose patients at scale. With Google as a third ally, it improves diagnostics and allows remote monitoring of patients through ECGs performed with wearable. Another milestone is the establishment Catalyst NetworkAstraZeneca’s interconnected global network of more than 20 interlocutor500 agreements, 100 solutions in development and 300 startups. Wera Telefonica It is an open innovation initiative of the Spanish telecom company, in which the pharmaceutical company promotes projects in areas such as oncology, cardiovascular, renal and metabolic diseases. In addition, AstraZeneca also works with EIT Health, Fitbit, the University of Navarra and the Polytechnic University of Barcelona.